|Systematic (IUPAC) name|
|Molar mass||186.233 g/mol|
|(what is this?)|
Mafenide is used to treat severe burns. It is used topically as an adjunctive therapy for second- and third-degree burns. It is bacteriostatic against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa. Some sources state that mafenide is more appropriate for non-facial burns, while chloramphenicol/prednisolone or bacitracin are more appropriate for facial burns.
Mechanism of action
Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns.
|This section does not cite any sources. (September 2014)|
Adverse reactions can include superinfection, pain or burning upon application, rash, pruritus, tachypnea, or hyperventilation. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could potentially result in metabolic acidosis.
There are no significant interactions.
Mafenide is contraindicated in those with sulfonamide hypersensitivity or renal impairment.
For use as adjunctive therapy for second- and third-degree burns to prevent infection, adults and children should apply topically to a thickness of approximately 1.6 mm to cleaned and debrided wound once or twice per day with a sterile gloved hand. The burned area should be covered with cream at all times.
- Siuda J. F., Cihonski C. D. (1972). "New compounds: carbamate derivatives of mafenide (homosulfanilamide)". J. Pharm. Sci. 61 (11): 1856–1857. doi:10.1002/jps.2600611143. PMID 4652670.
- Haynes B. (1971). "Mafenide acetate in Burn Treatment". New England J. Medic. 284 (23): 1324. doi:10.1056/NEJM197106102842310. PMID 5576444.
- Haik J, Ashkenazy O, Sinai S, et al. (November 2005). "Burn care standards in Israel: lack of consensus". Burns 31 (7): 845–9. doi:10.1016/j.burns.2005.04.012. PMID 15967581.